Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The commodities, which were flagged off by Health Cabinet Secretary Deborah Barasa on Friday, March 14, include ARV drugs ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

HIV commodities worth about Sh30 billion are lying at the Mombasa Road warehouses of the Mission for Essential Drugs & Supplies (MEDS), awaiting distribution, the NSDCC has said.The consignment ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...